GlassScriptPhysician profile
Aisha M Khan
NPI 1851911416
$3,103.50
in general payments reported to CMS, 2019-2025
31 companies · $1,127 in 2025
The $1,127 reported for 2025 was more than what 82% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $492 · 2022: $591 · 2023: $337 · 2024: $557 · 2025: $1,127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,021.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,020.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $470.80 | 2021-2025 | |
| Novo Nordisk INC | $422.65 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Otsuka America Pharmaceutical, INC. | $207.10 | 2021-2023 | Rexulti, Abilify Maintena |
| Ascensia Diabetes Care US INC. | $172.94 | 2024 | |
| Sequel Med Tech, LLC | $171.15 | 2025 | Twiist |
| Medtronic, INC. | $168.91 | 2024-2025 | Minimed 780g |
| Teva Pharmaceuticals USA, INC. | $165.34 | 2021-2022 | |
| Lundbeck LLC | $165.13 | 2021-2023 | Rexulti, Abilify Maintena |
| Amgen INC. | $140.93 | 2025 | Tepezza |
| Neurocrine Biosciences, INC. | $134.96 | 2021-2023 | Ingrezza |
| Lilly USA, LLC | $122.68 | 2023-2025 | Jardiance, Zepbound, Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $117.43 | 2021-2023 | Trintellix |
| Corium, LLC | $112.91 | 2021-2023 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $62.80 | 2022-2023 | |
| Corcept Therapeutics | $58.31 | 2024 | Korlym |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $56.89 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.63 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.78 | 2025 | Jardiance |
| Acella Pharmaceuticals, LLC | $33.47 | 2025 | NP Thyroid 60 |
| Radius Health, INC. | $31.80 | 2025 | Tymlos |
| Dexcom, INC. | $29.39 | 2025 | Dexcom G6 Transmitter |
| Recordati_rare_diseases_inc. | $27.01 | 2024 | Isturisa, Signifor Lar |
| Glaxosmithkline, LLC. | $22.38 | 2025 | Shingrix |
| Amneal Pharmaceuticals LLC | $21.64 | 2024 | Unithroid |
| Embecta Corp. | $19.53 | 2024 | Bd Nano 2nd Gen Pen Needle |
| Azurity Pharmaceuticals, INC. | $18.08 | 2025 | Azmiro |
| Ascendis Pharma Endocrinology INC | $17.51 | 2025 | Yorvipath |
| Supernus Pharmaceuticals, INC. | $17.25 | 2022 | |
| Xeris Pharmaceuticals, INC. | $17.11 | 2024 | Recorlev |
| Antares Pharma, INC. | $14.88 | 2025 | Xyosted |
| Theracosbio, LLC | $12.11 | 2024 | Brenzavvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aisha Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.